Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

New Technology

18 Sep 2006 08:46

Timestrip PLC18 September 2006 TIMESTRIP PLC ("Timestrip" or the "Company") Technology Breakthrough Timestrip develops new label technology for vaccines Timestrip Plc, which develops and markets unique label technologies, is delighted to announce that it has developed a label that is capable of recordingwhether temperature sensitive products have been accidentally frozen during transport or storage. The iStripTM is a patent pending label which undergoes an irreversible colour change when exposed to freezing temperatures. Developed in response to demand from the pharmaceutical industry, iStripTM is designed to be mass-produced at low cost and to be fully integrated into the packaging of products such as vaccines, protein based pharmaceuticals, foodstuffs and fertilizer. Accidental freezing of Diptheria, Tetanus, Pertussis and Hepatitis B vaccines, and combination vaccines, can compromise their immunological potency. Recent studies in the UK, USA, Canada, Pakistan, Malaysia, Hungary, Mongolia and other countries have found widespread freezing at many levels of the vaccine distribution system. The high incidence of this problem and the resulting health risks have made the monitoring and elimination of accidental freezing a priority for organizations such as WHO, UNICEF and PATH (Program for AppropriateTechnology in Health). Paul Freedman, Joint CEO of Timestrip Plc, commented: "Current indicators cost up to $3.50 per item and can only be used at case or pallet level - iStripTM will be marketed at a fraction of this cost, making it acost effective option at an individual product level. We believe that the cost-benefit attractions of the technology make it a potential candidate for adoption as a stipulated feature on vaccines. We are currently in discussions with manufacturers, distributors and global health organizations and are targeting initial revenues towards the end of 2007." Enquiries: Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc 01462 440 700Shane Dolan, Biddicks 020 7448 1000Fergus Marcroft, Evolution Securities 020 7071 4300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th Jun 20267:00 amRNSLending Book Milestone & Notice of Q4 Update
24th Mar 20267:00 amRNSQ3 Trading Update
16th Mar 20267:00 amRNSNotice of Trading Update
16th Mar 20267:00 amRNSNotice of Trading Update
27th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSHalf-Year Trading Update & Notice of Results
19th Nov 20257:00 amRNSGrant of 2025 LTIP Awards
14th Nov 20251:57 pmRNSExercise of Options & Director/PDMR Shareholdings
12th Nov 20257:00 amRNSLoan Book Update
6th Nov 202512:07 pmRNSResult of AGM
28th Oct 20257:00 amRNSNotice of Trading Update & Investor Presentations
3rd Oct 20257:00 amRNSVesting of Option Awards
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSNotice of AGM
24th Sep 20257:01 amRNSQ1 Trading Update
24th Sep 20257:00 amRNSFinal Results
18th Sep 20257:00 amRNSNotice of Results, Investor Presentation and AGM
1st Aug 20257:00 amRNSExtended Funding Facilities
26th Jun 20257:00 amRNSTrading Update and Notice of Final Results
4th Jun 20257:00 amRNSLaunch of New Investor Hub
6th May 20257:00 amRNSNotice of Q4 Trading Update and of Final Results
25th Mar 20257:00 amRNSQ3 Trading Update
12th Mar 20257:00 amRNSNotice of Investor Presentation
3rd Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSDirector/PDMR Shareholding
27th Feb 202512:00 pmRNSNotice of Trading Update
11th Feb 20257:00 amRNSLending Portfolio Update
28th Jan 20257:00 amRNSInterim Results
19th Dec 20247:00 amRNSHalf-Year Trading Update & Notice of Results
22nd Nov 20249:03 amRNSHolding(s) in Company
12th Nov 20247:00 amRNSTrading Update
5th Nov 202412:30 pmRNSResult of AGM
24th Oct 20247:00 amRNSExercise of Options & Director/PDMR Shareholdings
4th Oct 20247:00 amRNSVesting of Option Awards
3rd Oct 20247:00 amRNSDirector share purchases
2nd Oct 20247:00 amRNSExtended & Improved £65m NatWest Funding Facility
26th Sep 20247:00 amRNSNotice of AGM
25th Sep 20247:01 amRNSQ1 Trading Update
25th Sep 20247:00 amRNSFinal Results
10th Sep 20247:00 amRNSNotice of Results, Investor Pres & Trading Update
27th Aug 20247:00 amRNSGrowth Guarantee Scheme Accreditation
3rd Jul 20247:00 amRNSDirector Share Purchase
27th Jun 20247:00 amRNSTrading Update and Notice of Final Results
3rd Apr 20247:00 amRNSExtended & Improved £64m Funding Facility
26th Mar 20247:00 amRNSQ3 Trading Update
5th Mar 20247:00 amRNSNotice of Trading Update
25th Jan 20247:00 amRNSInterim Results
18th Jan 20244:30 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSHalf-Year Trading Update & Notice of Results
21st Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.